Evidence map›Paper›PMID 12208784›Full record

ArticleBritish journal of pharmacology2002

Functional characterization and biomarker identification in the Brown Norway model of allergic airway inflammation.

Stephen L Underwood, El-Bdaoui Haddad, Mark A Birrell, Kerryn McCluskie, Michaela Pecoraro, Dominika Dabrowski, Stephen E Webber, Martyn L Foster, Maria G Belvisi

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Lipopolysaccharide-induced injury is more pronounced in fetal transgenic ErbB4-deleted lungs.American journal of physiology. Lung cellular and molecular physiology · 2011
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Stephen L UnderwoodDepartment of Respiratory Disease, Aventis Pharma, Route 202-206, Bridgewater, New Jersey, NJ 07928, USA.
El-Bdaoui Haddad
Mark A Birrell
Kerryn McCluskie
Michaela Pecoraro
Dominika Dabrowski
Stephen E Webber
Martyn L Foster
Maria G Belvisi
Imperial College London · GBGlaxoSmithKline (United Kingdom) · GBLoughborough University · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

1. The antigen-induced inflammatory response in the Brown Norway rat is a model commonly used to assess the impact of novel compounds on airway eosinophilia. A detailed functional, cellular and molecular characterization of this model has not yet been performed within a single study. This information together with the temporal changes in this phenomenon should be known before this model can be used, with confidence, to elucidate the mechanisms of action of novel anti-inflammatory drugs. 2. Antigen challenge caused an accumulation of eosinophils in lung tissue 24 h after challenge. Accumulation of CD2(+) T cells was not apparent until after 72 h. 3. Interestingly, mRNA for the Th2 type cytokines interleukin (IL)-4, IL-5 and IL-13 and eotaxin were elevated in lung tissue after challenge and the expression of IL-13 and eotaxin protein increased at around 8-12 h. The temporal changes in both the biomarker production and the functional responses are important factors to consider in protocol design prior to initiating a compound screening program. 4. A neutralising antibody (R73) against alphabeta-TCR caused a significant reduction in T cell numbers accompanied by a significant suppression of eosinophil accumulation. 5. Airway hyperreactivity (AHR) was not apparent in this specific Brown Norway model in sensitized animals after a single or multiple challenges although eosinophil influx was seen in the same animals. 6. In conclusion, this is a convenient pre-clinical model (incorporating the measurement of biomarkers and functional responses) for screening novel small molecule inhibitors and/or biotherapeutics targeted against T cell/eosinophil infiltration/activation.

Indexed as

Disease Models, AnimalAnimalsBiomarkersBronchial HyperreactivityChemokine CCL11Chemokines, CCCytokinesEosinophiliaEosinophilsHypersensitivityInflammationLungLung DiseasesMaleRatsRats, Inbred BNBiomarkersCcl11 protein, ratChemokine CCL11Chemokines, CCCytokinesReceptors, Antigen, T-Cell, alpha-betaRNA, Messenger

Identifiers

PMID12208784
PMCPMC1573488
OpenAlexW2072132671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.